Company news
Nurexone Biologic Inc news in 2025
Nurexone Biologic Inc's news releases, calls and decks from 2025, newest first.
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
December 19, 2025
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
December 12, 2025
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 28, 2025
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
November 12, 2025
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
November 3, 2025
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
October 21, 2025
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
October 8, 2025
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
September 16, 2025
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
September 11, 2025
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
September 8, 2025
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
August 28, 2025
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
August 20, 2025
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
August 8, 2025
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
July 25, 2025
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
July 8, 2025
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
June 20, 2025
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
June 4, 2025
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
May 30, 2025
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 27, 2025
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
May 8, 2025
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
May 2, 2025
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
April 24, 2025
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
April 22, 2025
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 9, 2025
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
April 4, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
March 14, 2025
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
March 10, 2025
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
February 27, 2025
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
February 19, 2025
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 14, 2025
Decks in 2025
- Investor Presentation (December 2025)
Investor deck · 17 slides · December 2025
- Investor Presentation (May 2025)
Investor deck · 17 slides · May 2025
- Investor Presentation (2025)
Investor deck · 17 slides · 2025